Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689158 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL8766281 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL9721425 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL1805658 | 0.79 | RXFP1 (0.56) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL5545365 | 0.79 | GAA (0.55) | ALDH1A1POLBMAPK1SMN1; SMN2HTT | |
| SCHEMBL6326388 | 0.79 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL10828925 | 0.79 | RAB9A (0.45) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL1534062 | 0.78 | CETP (0.65) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL4938228 | 0.78 | KMT2A (0.62) | ALDH1A1HPGDCYP2C19POLBMAPK1 | |
| SCHEMBL29651063 | 0.78 | KMT2A (0.62) | ALDH1A1HPGDCYP2C19POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | claimed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | claimed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | claimed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | claimed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | claimed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | claimed |
| EP-0858455-A4 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO INC (US) | 2000-04-12 | — | — | EP | claimed |
| US-5998464-A | 4-Oxa and 4-thia steroids | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5817802-A | IN IONIZING MEDIUM WITH A TRIALKYLSILANE | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | claimed |
| EP-0858455-A1 | 4-OXA AND 4-THIA STEROIDS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | claimed |
| US-5777134-A | 4-oxa and 4-thia steriods | MERCK & CO., INC. (US) | 1998-07-07 | — | — | US | claimed |
| US-5696266-A | HYDROGENATING DELTA-5-STEROIDAL ENELACTAM DISSOLVED IN SOLVENT IN PRESENCE OF RHODIUM CATALYST | MERCK & CO., INC. (US) | 1997-12-09 | — | — | US | claimed |
| WO-1997015564-A1 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | claimed |
| US-10190009-B2 | Ink composition, ink jet recording method using same, and colored material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20160160065-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-0246616-A2 | Silver halide color photographic material | Fuji Photo Film Co., Ltd. (JP) | 1987-11-25 | — | — | EP | disclosed |
| US-4009038-A | CYAN COUPLER, A 2-(2'-HYDROXYPHENYL)BENZOTRIAZOLE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | ALDH1A1 4570/4885HPGD 2659/4885CYP2C19 2118/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 2723/4885HPGD 3704/4885CYP2C19 1220/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 2723/4885HPGD 3704/4885CYP2C19 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.